What factors have contributed to the revival of research on therapeutic uses of psychedelics?
What factors have contributed to the revival of research on the therapeutic use of LSD, psilocybin and MDMA in the USA and other countries, over 25 years after their nonmedical use was banned? How is current research on their therapeutic use related to research done in the 1950s and 1960s? What disorders are these drugs being used to treat? What has the research shown to date? What are the researchers’ and funders’ goals? What does the research suggest about how we should regulate the use of psychedelic drugs for medical and nonmedical use?
Wayne Hall is a Professorial Fellow at the National Centre for Youth Substance Use Research at the University of Queensland and the Queensland Alliance for Environmental Health Sciences. He was: a Professor at the National Addiction Centre, Kings College London (2014-2019); Director of Centre for Youth Substance Abuse Research (2014-2016), NHMRC Australia Fellow, the University of Queensland Centre for Clinical Research (2009-2014), Professor of Public Health Policy, School of Population Health (2005-2009), Director of the Office of Public Policy and Ethics, Institute for Molecular Bioscience (2001-2005) and Executive Director of the National Drug and Alcohol Research Centre (1994-2001). He has advised the World Health Organization on the health effects of cannabis use; the effectiveness of drug substitution treatment; the contribution of illicit drug use to the global burden of disease; and the ethical implications of genetic and neuroscience research on addiction.